Filters
New drug applications approved by US FDA as of 01-15 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Using methylphenidate and a selective serotonin reuptake inhibitor (SSRI) together does not appear to pose any significant risk, with both agents having been shown to be safe in adolescent patients with attention deficit-hyperactivity disorder (ADHD) and depression, according to a new-user cohort study.
Being born small for gestational age (SGA) appears to contribute to a reduced lung function during middle age, reveals a study.
Children born to mothers who were taking pravastatin during the second and third trimesters of pregnancy do not appear to have any identifiable long-term neurodevelopmental safety risks, as reported in a study.
Prenatal exposure to plastic-derived chemicals, such as bisphenol A (BPA) and phthalates, tends to increase the risk of asthma, particularly in males, a study has shown.
Consumption of sugar-sweetened beverages (SSBs) may lead to higher body mass index (BMI) and body weight in both children and adults, as shown in a systematic review and meta-analysis.
New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with either labetalol or nifedipine is similarly effective in reducing adverse maternal outcomes among women with mild chronic hypertension (CHTN) in pregnancy, according to a study presented at SMFM 2023.
Nightly use of 0.05% atropine eye drops among children appears to lead to a significantly lower incidence of near-sightedness, as shown in the results of the LAMP2 study from Hong Kong.
New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
